Lv61
2253 积分 2022-07-20 加入
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4小时前
待确认
Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review
14天前
已完结
Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold
25天前
已完结
Comparing welfare estimates from payment card contingent valuation and discrete choice experiments
26天前
已完结
First report of incidence of adult myelodysplastic syndrome in China
26天前
已完结
Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry
26天前
已完结
Ixekizumab or secukinumab in psoriasis: what difference does it make?
1个月前
已完结
Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A
1个月前
已完结
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies
1个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
皖公网安备34019202002308
